Dermime S, Barrett J, Gambacorti-Passerini C
Bone Marrow Transplantation Unit, NHLBI, NIH, Bethesda, Maryland, USA.
Drugs Aging. 1995 Oct;7(4):266-77. doi: 10.2165/00002512-199507040-00002.
In the last 5 years significant progress has been made in our understanding of the molecular nature of anti-tumour T cell-mediated responses. This review describes the involvement of the cellular immune system in the recognition and destruction of cancer cells. Four aspects are discussed: (i) the generalized immune activation induced by the systemic administration of cytokines, in particular, interleukin-2; (ii) the specific T cell-mediated reactions against tumour cells through the recognition of tumour-associated molecules, 1) and tyrosinase proteins described in melanomas, and minor histocompatibility antigens in the setting of allogenic bone marrow transplantation for leukaemia; (iii) the potentially significant but still hypothetical immune-mediated recognition of molecules either tumour-associated or transformation-related (including altered oncogenic proteins); and (iv) the role of co-stimulatory molecules in the induction of tumour-specific immunity. The current and future therapeutic applications in cancer treatment and potential limitations in this approach are discussed.
在过去5年里，我们对抗肿瘤T细胞介导反应的分子本质的理解取得了重大进展。本综述描述了细胞免疫系统在识别和破坏癌细胞中的作用。讨论了四个方面：（i）通过全身给予细胞因子，特别是白细胞介素-2诱导的全身性免疫激活；（ii）通过识别肿瘤相关分子对肿瘤细胞的特异性T细胞介导反应，1）黑色素瘤中描述的酪氨酸酶蛋白，以及白血病同种异体骨髓移植情况下的次要组织相容性抗原；（iii）对肿瘤相关或转化相关分子（包括改变的致癌蛋白）潜在重要但仍属假设的免疫介导识别；（iv）共刺激分子在诱导肿瘤特异性免疫中的作用。讨论了目前和未来在癌症治疗中的治疗应用以及这种方法的潜在局限性。
